BACKGROUND: Refractory sprue is defined as primary or secondary failure to respond to a gluten free diet in patients with coeliac disease-like enteropathy and may signify cryptic or overt enteropathy associated T cell lymphoma. AIMS: To study in detail jejunal morphology and immunophenotypes in patients with refractory sprue in the search for features that might be useful to predict prognosis. PATIENTS: Seven patients are described, representing all such cases identified in our hospital over a 13 year period. METHODS: Biopsy and/or surgical resection specimens were examined by morphology, immunohistochemistry, including enzymatic and immunofluorescent detection, and molecular biology. RESULTS: All patients had phenotypically abnormal intraepithelial lymphocytes (IELs) that lacked CD8, T cell receptor alpha beta (or gamma delta), and/or expressed CD30 in addition to variable expression of the natural killer cell receptor CD94. A monoclonal T cell population was present in six cases, data from the seventh being inconclusive. Three patients had overt lymphoma with CD30+ tumour tissue intervening between intact mucosa that contained neoplastic IELs. Intriguingly, CD30+ IELs were observed both a long way away from, and in direct continuity with, the tumours in these patients. Such CD30+ cells were hardly detected in patients without tumours, two of which are in good health several years after the initial diagnosis. CONCLUSIONS: Our data suggest that abnormal IELs in patients with refractory sprue are phenotypically heterogeneous. CD30 expression by these cells may indicate a worse prognosis, including the occurrence of overt lymphoma.
BACKGROUND: Refractory sprue is defined as primary or secondary failure to respond to a gluten free diet in patients with coeliac disease-like enteropathy and may signify cryptic or overt enteropathy associated T cell lymphoma. AIMS: To study in detail jejunal morphology and immunophenotypes in patients with refractory sprue in the search for features that might be useful to predict prognosis. PATIENTS: Seven patients are described, representing all such cases identified in our hospital over a 13 year period. METHODS: Biopsy and/or surgical resection specimens were examined by morphology, immunohistochemistry, including enzymatic and immunofluorescent detection, and molecular biology. RESULTS: All patients had phenotypically abnormal intraepithelial lymphocytes (IELs) that lacked CD8, T cell receptor alpha beta (or gamma delta), and/or expressed CD30 in addition to variable expression of the natural killer cell receptor CD94. A monoclonal T cell population was present in six cases, data from the seventh being inconclusive. Three patients had overt lymphoma with CD30+ tumour tissue intervening between intact mucosa that contained neoplastic IELs. Intriguingly, CD30+ IELs were observed both a long way away from, and in direct continuity with, the tumours in these patients. Such CD30+ cells were hardly detected in patients without tumours, two of which are in good health several years after the initial diagnosis. CONCLUSIONS: Our data suggest that abnormal IELs in patients with refractory sprue are phenotypically heterogeneous. CD30 expression by these cells may indicate a worse prognosis, including the occurrence of overt lymphoma.
Authors: P Brandtzaeg; T S Halstensen; K Kett; P Krajci; D Kvale; T O Rognum; H Scott; L M Sollid Journal: Gastroenterology Date: 1989-12 Impact factor: 22.682
Authors: M W Bekkenk; F A Geelen; P C van Voorst Vader; F Heule; M L Geerts; W A van Vloten; C J Meijer; R Willemze Journal: Blood Date: 2000-06-15 Impact factor: 22.113
Authors: C Cellier; E Delabesse; C Helmer; N Patey; C Matuchansky; B Jabri; E Macintyre; N Cerf-Bensussan; N Brousse Journal: Lancet Date: 2000-07-15 Impact factor: 79.321
Authors: J Spencer; N Cerf-Bensussan; A Jarry; N Brousse; D Guy-Grand; A S Krajewski; P G Isaacson Journal: Am J Pathol Date: 1988-07 Impact factor: 4.307
Authors: B Jabri; N P de Serre; C Cellier; K Evans; C Gache; C Carvalho; J F Mougenot; M Allez; R Jian; P Desreumaux; J F Colombel; C Matuchansky; H Cugnenc; M Lopez-Botet; E Vivier; A Moretta; A I Roberts; E C Ebert; D Guy-Grand; N Brousse; J Schmitz; N Cerf-Bensussan Journal: Gastroenterology Date: 2000-05 Impact factor: 22.682
Authors: T T Salmi; P Collin; I R Korponay-Szabó; K Laurila; J Partanen; H Huhtala; R Király; L Lorand; T Reunala; M Mäki; K Kaukinen Journal: Gut Date: 2006-03-29 Impact factor: 23.059
Authors: Bertrand Meresse; Shane A Curran; Cezary Ciszewski; Gerasim Orbelyan; Mala Setty; Govind Bhagat; Leanne Lee; Maria Tretiakova; Carol Semrad; Emily Kistner; Robert J Winchester; Veronique Braud; Lewis L Lanier; Daniel E Geraghty; Peter H Green; Stefano Guandalini; Bana Jabri Journal: J Exp Med Date: 2006-05-08 Impact factor: 14.307
Authors: Alexandra Fernandes; Ana Margarida Ferreira; Rosa Ferreira; Sofia Mendes; Cláudia Agostinho; Nuno Almeida; Pedro Figueiredo; Manuela Ferreira; Pedro Amaro; Lígia Prado E Castro; Carlos Sofia Journal: GE Port J Gastroenterol Date: 2015-09-26